Community Health Media
  • Home
  • What We Do
  • Playlists
  • Content Library
    • HER2+
    • HR+
    • HER2-Low / Ultra-Low
    • Triple Negative
    • High Risk
  • Podcasts
    • Breast Friends
    • Apple Podcasts
    • Spotify
    • Amazon Music
    • iHeartRadio
    • Castbox
    • Goodpods
    • Pocket Casts
  • Contact Us
  • ···
        • Youtube
        • Facebook
        • LinkedIn
        • Instagram
    Community Health Media
    • Home
    • What We Do
    • Playlists
    • Content Library
      • HER2+
      • HR+
      • HER2-Low / Ultra-Low
      • Triple Negative
      • High Risk
    • Podcasts
      • Breast Friends
      • Apple Podcasts
      • Spotify
      • Amazon Music
      • iHeartRadio
      • Castbox
      • Goodpods
      • Pocket Casts
    • Contact Us
    • ···
          • Youtube
          • Facebook
          • LinkedIn
          • Instagram
      Community Health Media
      • Home
      • What We Do
      • Playlists
      • Content Library
        • HER2+
        • HR+
        • HER2-Low / Ultra-Low
        • Triple Negative
        • High Risk
      • Podcasts
        • Breast Friends
        • Apple Podcasts
        • Spotify
        • Amazon Music
        • iHeartRadio
        • Castbox
        • Goodpods
        • Pocket Casts
      • Contact Us

      Capecitabine Comfort vs ADC Leap

      Dr. Mouabbi voices the field’s discomfort with bypassing capecitabine after DB-06 made it the comparator arm. Dr. Cairo counters that capecitabine is “endocrine adjacent” but may fail the rapid progressors who really need an ADC first.

      FacebookXRedditPinterestEmail

      You may also like

      Video

      Dr. Jason Mouabbi & Dr. Michelina Cairo – Talking DB04 and DB06

      2 min read
      Video

      Concurrent Endocrine: Old-School?

      1 min read
      Video

      DB-04 to DB-06, the Steps of Ultra-Low

      1 min read
      Video

      Ultra-Low in Real Life

      1 min read
      Video

      Any HER2 Ever?

      1 min read
      Video

      First-Strike

      1 min read

      Recommended Videos

      Rethinking First-Line Metastatic HER2+ Therapy with T-DXd – Drs. Mouabbi, O’Shaughnessy & Rimawi

      4 months ago

      Is T-DXd Rewriting First-Line HER2+ Metastatic Breast Cancer? – Dr. Mark Pegram & Dr. Fengting Yan

      4 months ago

      Is HER2+ Metastatic Breast Cancer Curable? What Comes Next – Dr. Gregory Vidal & Dr. Nusayba Bagegni

      4 months ago

      DESTINY-Breast09 & the Future of Care – Dr. Irene Kang & Dr. Aditya Bardia

      4 months ago

      Community Health Ventures

      Address:

      2471 18th St NW
      Second Floor
      Washington, DC 20009

      Email: info@communityhealth.media

      Follow Us

      • youtube
      • facebook
      • linkedin
      • instagram

      Quick Links

      • About
      • KOL Playlists
      • Contact Us
      • Privacy Policy
      • Terms of Use

      Content By Topics

      • HER2+
      • HR+
      • Triple Negative
      • HER2-Low / Ultra-Low
      • High Risk

      Podcast Network

      • Breast Friends Podcast
      • Apple Podcasts
      • Spotify
      • Amazon Music
      • Castbox
      • Goodpods
      • iHeartRadio
      • Pocket Casts
      © 2026 Community Health Technologies, Inc. All Rights Reserved